Stock Taper Revenue: Record first-quarter revenue at the higher end of expectations, reflecting a 1.4% increase on a reported basis and over 12% growth when excluding a large former client under a transition-of-care agreement.
Net Income: Exceeded guidance, contributing to strong earnings per share (EPS).
Adjusted EBITDA: Also above guidance, with a healthy margin maintained despite ongoing investments.
Operating Cash Flow: Approximately $446 million, with $200 million maintained on a trailing twelve-month basis.
Share Repurchase: Completed a $200 million share repurchase program, buying back over 8.8 million shares.
Member Engagement: Healthy engagement levels, with utilization trending towards the high end of historical ranges.
Market Activity: Positive momentum in the selling season, with early commitments from clients, particularly from those who had previously delayed decisions.
Partnerships: Strong traction with health plan partners, notably Cigna, and positive reception for the Progyny Select offering.
Third-party Study: A significant client shared positive outcomes from Progyny's program, reinforcing the value proposition of their services.
Q2 Revenue Guidance: Projected between $1.365 billion to $1.405 billion, reflecting growth of 5.9% to 9%.
Full-Year Expectations: Increased adjusted EBITDA guidance to $232 million to $244 million, with net income projected at $103.7 million to $112.3 million, indicating strong growth potential for the year.
Utilization Assumptions: Maintaining full-year assumptions of 1.04% to 1.05% for utilization rates.
Headwinds: Concerns about potential negative impacts on member engagement and employer demand, although management believes these are more related to market perceptions than actual shifts in dynamics.
RFP Activity: Fewer RFPs from existing clients compared to expectations, though new business opportunities from competitors are increasing.
Market Dynamics: The overall fertility rate in the U.S. is declining, which could impact long-term demand for services.
Sales Activity: Early commitments are primarily from clients who had previously delayed decisions, indicating a positive shift in market sentiment.
Utilization Drivers: Higher utilization rates are attributed to a favorable mix of new clients from specific industries rather than increased demand from existing clients.
Upselling Opportunities: Management is optimistic about upselling but noted that significant impacts from these activities are generally seen in subsequent years.
Market Reception: Positive feedback on Progyny Select, but pull-through expected later in the year as small employers finalize decisions. Overall, Progyny, Inc. reported a strong start to 2026, with positive financial results, strategic initiatives aimed at growth, and an optimistic outlook for the remainder of the year, despite some market challenges and headwinds.
SOURCE: Q1 2026 EARNINGS CALL TRANSCRIPT